ClinicalTrials.gg
Not yet recruitingNCT07812480Updated Sep 10, 2026

Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia

An observational study in Dementia Disorders and Mild Cognitive Impairment (MCI), sponsored by Assiut University. Not yet recruiting. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
75
Ages
50 Years and older
Sex
All
01

Study summary

Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI scan, and a brain wave test (EEG). The goal is to see whether combining these three tests can help doctors tell the difference between normal aging, MCI, and dementia more accurately, and whether this approach works well in an Egyptian population, including all common causes of dementia (not only Alzheimer's disease).

Adults aged 50 to 85 will be placed into one of three groups: those with normal memory, those with mild memory problems (MCI), and those with dementia. Everyone will have a memory and thinking assessment, a blood draw, a brain MRI, and a brain wave (EEG) recording. No new medication or treatment is given as part of this study; it involves only assessment and testing. The information gathered may help doctors diagnose memory problems earlier and more accurately in the future.

Read the detailed description

This is a cross-sectional, observational, case-control study designed to characterize and compare plasma glial fibrillary acidic protein (GFAP), quantitative electroencephalography (EEG), and MRI-based brain volumetry across three groups: healthy controls, participants with mild cognitive impairment (MCI), and participants with dementia of any etiology (Alzheimer's, vascular, Lewy body, frontotemporal, or mixed).

Plasma GFAP, an astrocytic activation marker, will be quantified from EDTA-collected blood via automated chemiluminescent immunoassay (Lumipulse or Alinity platform where available) or conventional ELISA. Structural brain volumetry (hippocampal, medial temporal, and whole-brain/ventricular volumes) will be derived from 3-Tesla MRI using a 3D T1-weighted MPRAGE sequence with automated segmentation. Resting-state EEG will be recorded using a 19-channel 10-20 electrode montage for quantitative spectral power analysis across standard frequency bands.

All participants will undergo a standardized clinical and psychometric assessment, including the Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), and functional assessment via the Katz Index and Lawton-Brody Instrumental Activities of Daily Living scale, to confirm group classification prior to biomarker collection.

The study addresses a gap in the literature: although plasma GFAP, MRI volumetry, and EEG have each been separately validated as markers of neurodegeneration, few studies have jointly acquired all three modalities within a single cohort spanning the full continuum from normal cognition through dementia, and fewer still have done so in an Egyptian or broader Middle East/North Africa population across all dementia etiologies rather than Alzheimer's disease alone. Findings from this study are intended to inform the development of a combined biomarker panel for earlier and more accurate differentiation between normal cognitive aging, MCI, and dementia.

02

Conditions studied

  • Dementia Disorders
  • Mild Cognitive Impairment (MCI)

Keywords

  • dementia
  • cognition
  • mild cognitive impairment
  • GFAP
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 75 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study will include three groups matched for age, sex and educational level: from Outpatient clinic of the Department of Neurology and Psychiatry, Assiut University Hospitals healthy controls, patients with mild cognitive impairment (MCI), and patients with dementia of any etiology (Alzheimer's, vascular, Lewy body, frontotemporal and mixed dementia)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Dementia diagnosed according to DSM -5\ with a total score \< 24 (or \< 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \< 79 to confirm cognitive impairment.
  2. Mild cognitive impairment diagnosed according to established diagnostic criteria according to DSM -5.
  3. Men or women of at least 50 years of age.
  4. Reliable in individual data and willing to make themselves available for the duration of the study.
  5. Clear written obtained from a first-degree relative for each patient participant, and from the control participant himself/herself.

Exclusion criteria

Exclusion Criteria:

  • age below 50 years .

    • other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, , or infectious disease; metallic objects in the body; craniotomy in the past.
    • Presence of medical or psychiatric condition that may increase the risk associated with the study
    • MRI (pacemaker, metallic implants, severe claustrophobia).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dementia

    according toDSM -5 , with a total Mini-Mental State Examination score \< 24 (or \< 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \< 79 to confirm cognitive impairment

  • Mild Cognitive impairment

    impairment diagnosed according to established diagnostic criteria

  • control

    healthy group matched age, sex

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Glial Fibrillary Acidic Protein (GFAP)main outcome

    Measured in picograms per milliliter (pg/mL) via automated chemiluminescent immunoassay (Lumipulse or Alinity platform) or ELISA, from venous blood collected in EDTA tubes

    Time frame: Baseline (single time point)

  2. Hippocampal Volume on MRI, Whole-Brain Volume on MRI,Ventricular Volume on MRI

    Measured in cubic millimeters (mm³), normalized to total intracranial volume, derived from 3-Tesla 3D T1-weighted MPRAGE MRI using automated segmentation software (FreeSurfer)

    Time frame: Baseline (single time point)

  3. EEG Band Power Alpha , beta , delta , theta

    Absolute spectral power (µV²) in the different frequency band , derived from resting-state EEG recorded with a 19-channel 10-20 electrode montage

    Time frame: Baseline (single time point)

Secondary outcomes

  1. Correlation Between Plasma GFAP and MRI Volumetric Measures Across Dementia Etiological Subtypes

    Pearson/Spearman correlation coefficient between plasma GFAP concentration (pg/mL) and MRI-derived regional brain volumes (mm³), calculated separately within Alzheimer's, vascular, Lewy body, frontotemporal, and mixed dementia subgroups

    Time frame: Baseline (single time point)

  2. Correlation Between Plasma GFAP and EEG Spectral Power Measures Across Dementia Etiological Subtypes

    Pearson/Spearman correlation coefficient between plasma GFAP concentration (pg/mL) and EEG band power (µV²), calculated separately within Alzheimer's, vascular, Lewy body, frontotemporal, and mixed dementia subgroups

    Time frame: Baseline (single time point)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 10, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Oct 10, 2028
CompletionEst.
Mar 10, 2029
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07812480
Lead sponsor
Assiut University
Responsible party
Abdelrahman Goda (Assistant lecturer, Assiut University) — Principal investigator
First posted
Sep 10, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 10, 2028 (estimated)
Completion
Mar 10, 2029 (estimated)
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion